CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It provides clinical development of aldoxorubicin oncology pipeline for the treatment of cancer. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
Market Cap | 21.341 Million | Shares Outstanding | 38.801 Million | Avg 30-day Volume | 102.633 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.04 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -6.79 Million |
Price to Book Value | 1.4609 | Operating Margin | 0.0 | Enterprise Value | 2.956 Million |
Current Ratio | 4.118 | EPS Growth | 0.136 | Quick Ratio | 3.606 |
1 Yr BETA | 0.5354 | 52-week High/Low | / | Profit Margin | 0.0 |
Operating Cash Flow Growth | -7.376 | Altman Z-Score | -53.2111 | Free Cash Flow to Firm | -4.574 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
SNOWDY STEPHEN CHIEF EXECUTIVE OFFICER |
|
0 | 2022-01-10 | 2 |
|
50,000 | 2021-12-15 | 3 | |
|
590,247 | 2020-08-14 | 0 | |
KRIEGSMAN STEVEN A CHIEF EXECUTIVE OFFICER |
|
3,668,038 | 2020-08-07 | 0 |
|
600,785 | 2020-08-07 | 0 | |
|
335,373 | 2020-08-07 | 0 | |
CALOZ JOHN Y CHIEF FINANCIAL OFFICER |
|
0 | 2019-12-13 | 0 |
CURTIS ERIC PRES., CHIEF OPERATING OFFICER |
|
0 | 2018-05-03 | 0 |
KRATZ FELIX VICE PRESIDENT DRUG DISCOVERY |
|
0 | 2017-12-15 | 0 |
CHAWLA SHANTA M.D. SENIOR VP-DRUG DEVELOPMENT |
|
2,100 | 2017-06-13 | 0 |
|
0 | 2016-12-15 | 0 | |
LEVITT DANIEL J EVP AND CHIEF MEDICAL OFFICER |
|
0 | 2016-12-15 | 0 |
WIELAND DOUGLAS SCOTT SR VP - DRUG DEVELOPMENT |
|
0 | 2016-12-15 | 0 |
|
0 | 2016-12-15 | 0 | |
WARE OLIVIA C CHIEF COMMERCIAL OFFICER |
|
0 | 2016-01-11 | 0 |
LEVIN BEN SVP-LEGAL AFFAIRS/GC/SECY |
|
0 | 2015-12-15 | 0 |
|
0 | 2015-12-15 | 0 | |
|
0 | 2015-12-15 | 0 | |
|
0 | 2014-12-15 | 0 | |
|
0 | 2013-12-10 | 0 | |
|
0 | 2013-12-10 | 0 | |
|
4,577,605 | 2013-12-10 | 0 | |
GEYER DAVID SCOTT SR. V.P. OF MANUFACTURING |
|
0 | 2011-12-12 | 0 |
BARBER JACK R CHIEF SCIENTIFIC OFFICER |
|
0 | 2009-07-01 | 0 |
SHAH JAISIM SR. VP - BUSINESS DEVELOPMENT |
|
0 | 2009-05-04 | 0 |
FOGELMAN MITCHELL K CHIEF FINANCIAL OFFICER |
|
0 | 2008-11-21 | 0 |
NG SHI CHUNG SR VP RESEARCH & DEVELOPMENT |
|
0 | 2008-11-21 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
CYTRX CORP CYTR | 2022-05-20 22:15:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 21:45:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 21:15:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 20:45:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 20:15:05 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 19:45:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 19:15:04 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 18:45:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 18:15:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 17:45:03 UTC | -1.7092 | 2.5292 | 1600000 |
CYTRX CORP CYTR | 2022-05-20 17:15:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 16:45:04 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 16:15:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 15:45:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 15:15:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 14:45:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 14:15:04 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 13:45:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 13:15:03 UTC | -1.7092 | 2.5292 | 1200000 |
CYTRX CORP CYTR | 2022-05-20 12:45:03 UTC | -1.7092 | 2.5292 | 1200000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|